Will watching TV definitely make you nearsighted? Two key reasons for medical exposure are driving north to urinate and acupuncture to improve overactive bladder. The "individualized treatment goal" of Yadong Hospital helps patients integrate into society, which makes them unable to work! Comprehensive care for rheumatoid arthritis reduces future disability

November every year is the International Prevention and Treatment Month of Lung Cancer. Dr. Chen Yumin, Director of General Thoracic Department, Taipei Rongzong Chest Department, said that the mortality rate of lung cancer has been the first for ten consecutive years, and the incidence rate of lung cancer in Taiwan Province is the second in Asia, and the probability of cancer cells metastasizing to the brain is extremely high, which has become a "new national disease".

more than half of the patients were diagnosed as advanced

Dr. Chen Yumin said that more than half of the patients in Taiwan Province were diagnosed as advanced, and 9% were non-small lung adenocarcinoma. Dr. Guo Zhixi, director of the Department of Lung Cancer and Endoscopy, Linkou Chang Gung Memorial Hospital, said that the existing third-generation ALK target drugs have been approved, breaking through the drug resistance limit, with a tumor response rate of 4% and a tumor remission duration of 6 months, which has a good therapeutic effect on brain metastasis. Now ROS1 target drugs are paid through health insurance, which can save patients more than 1.8 million yuan a year.

director Guo zhixi explained that according to foreign research, the tumor response rate of the third-generation ALK target drugs is nearly 4% for patients who have used the second-generation ALK target drugs or who are resistant to two or more ALK target drugs, regardless of whether chemotherapy is combined or not, and the tumor remission duration can be as high as nearly 6 months.

Compared with the first-generation target drugs, the third-generation ALK target drugs are easier to penetrate the brain barrier and enter the brain to control tumors, and the response rate to brain metastasis is over 5%. In patients who use more than two kinds of ALK target drugs, the tumor remission duration can be as long as 14.5 months.

At present, the third-generation ALK target drug has been officially approved in Taiwan Province, providing more treatment options for lung cancer patients who are resistant to the second-generation ALK target drug.

WHO: the incidence of lung cancer in Taiwan Province ranks 15th in the world and 2nd in Asia

the WHO study of the world health organization found that the incidence of lung cancer in Taiwan Province ranks 15th in the world and 2nd in Asia after North Korea. The incidence of female has even squeezed into the eighth place in the world, and lung cancer has become a "new national disease" in Taiwan Province! Chairman Chen Yumin shared that the number of lung cancer deaths reached a record high in 218, and according to the data, the age of lung cancer decreased, from 72 to 68 for men and 65 for women in the past ten years. Because the early symptoms of lung cancer were not obvious, more than half of the diagnoses were advanced, and chemotherapy and targeted treatment would be given priority in treatment.

the third generation of ALK target drugs is approved to reduce the burden on patients

Director Guo Zhixi said that lung adenocarcinoma is the majority of all lung cancer patients, and nearly 7% of lung adenocarcinoma patients have gene mutation, which is much higher than that in Europe and the United States. Nearly 55% of patients have EGFR (epidermal growth factor receptor) genotype, and only if the test results are negative will other genetic tests be carried out. However, nearly 1% of patients without EGFR mutation have ALK (anaplasticlymphomakinase) gene mutation. It is suggested that cancer friends should screen ALK and ROS1 (transmembrane receptor protein tyrosine kinase) genes simultaneously after diagnosis, so as to shorten the detection process.

Cai Lijuan, deputy executive director of Taiwan Province Cancer Foundation, said that after the approval of the third-generation ALK target drug, patients had the option of follow-up treatment, while the ROS1 target drug passed the health insurance, which further reduced the economic burden of patients' treatment. Topic: ROS1 target drug, WHO, Dr. Chen Yumin, Director of General Thoracic Department of Taipei Rongzong Chest Department, third-generation ALK target drug, lung adenocarcinoma.